Qutuba G Karwi1,2, Julia Bornbaum3, Kerstin Boengler3, Roberta Torregrossa4,5, Matthew Whiteman4, Mark E Wood5, Rainer Schulz3, Gary F Baxter1. 1. School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, UK. 2. College of Medicine, University of Diyala, Diyala, Iraq. 3. Institute of Physiology, Justus-Liebig-University, Giessen, Germany. 4. Medical School, University of Exeter, Exeter, UK. 5. School of Biosciences, University of Exeter, Exeter, UK.
Abstract
BACKGROUND AND PURPOSE: H2 S protects myocardium against ischaemia/reperfusion injury. This protection may involve the cytosolic reperfusion injury salvage kinase (RISK) pathway, but direct effects on mitochondrial function are possible. Here, we investigated the potential cardioprotective effect of a mitochondria-specific H2 S donor, AP39, at reperfusion against ischaemia/reperfusion injury. EXPERIMENTAL APPROACH: Anaesthetized rats underwent myocardial ischaemia (30 min)/reperfusion (120 min) with randomization to receive interventions before reperfusion: vehicle, AP39 (0.01, 0.1, 1 μmol·kg-1 ), or control compounds AP219 and ADT-OH (1 μmol·kg-1 ). LY294002, L-NAME or ODQ were used to investigate the involvement of the RISK pathway. Myocardial samples harvested 5 min after reperfusion were analysed for RISK protein phosphorylation and isolated cardiac mitochondria were used to examine the direct mitochondrial effects of AP39. KEY RESULTS: AP39, dose-dependently, reduced infarct size. Inhibition of either PI3K/Akt, eNOS or sGC did not affect this effect of AP39. Western blot analysis confirmed that AP39 did not induce phosphorylation of Akt, eNOS, GSK-3β or ERK1/2. In isolated subsarcolemmal and interfibrillar mitochondria, AP39 significantly attenuated mitochondrial ROS generation without affecting respiratory complexes I or II. Furthermore, AP39 inhibited mitochondrial permeability transition pore (PTP) opening and co-incubation of mitochondria with AP39 and cyclosporine A induced an additive inhibitory effect on the PTP. CONCLUSION AND IMPLICATIONS: AP39 protects against reperfusion injury independently of the cytosolic RISK pathway. This cardioprotective effect could be mediated by inhibiting PTP via a cyclophilin D-independent mechanism. Thus, selective delivery of H2 S to mitochondria may be therapeutically applicable for employing the cardioprotective utility of H2 S.
BACKGROUND AND PURPOSE:H2 S protects myocardium against ischaemia/reperfusion injury. This protection may involve the cytosolic reperfusion injury salvage kinase (RISK) pathway, but direct effects on mitochondrial function are possible. Here, we investigated the potential cardioprotective effect of a mitochondria-specific H2 Sdonor, AP39, at reperfusion against ischaemia/reperfusion injury. EXPERIMENTAL APPROACH: Anaesthetized rats underwent myocardial ischaemia (30 min)/reperfusion (120 min) with randomization to receive interventions before reperfusion: vehicle, AP39 (0.01, 0.1, 1 μmol·kg-1 ), or control compounds AP219 and ADT-OH (1 μmol·kg-1 ). LY294002, L-NAME or ODQ were used to investigate the involvement of the RISK pathway. Myocardial samples harvested 5 min after reperfusion were analysed for RISK protein phosphorylation and isolated cardiac mitochondria were used to examine the direct mitochondrial effects of AP39. KEY RESULTS:AP39, dose-dependently, reduced infarct size. Inhibition of either PI3K/Akt, eNOS or sGC did not affect this effect of AP39. Western blot analysis confirmed that AP39 did not induce phosphorylation of Akt, eNOS, GSK-3β or ERK1/2. In isolated subsarcolemmal and interfibrillar mitochondria, AP39 significantly attenuated mitochondrial ROS generation without affecting respiratory complexes I or II. Furthermore, AP39 inhibited mitochondrial permeability transition pore (PTP) opening and co-incubation of mitochondria with AP39 and cyclosporine A induced an additive inhibitory effect on the PTP. CONCLUSION AND IMPLICATIONS: AP39 protects against reperfusion injury independently of the cytosolic RISK pathway. This cardioprotective effect could be mediated by inhibiting PTP via a cyclophilin D-independent mechanism. Thus, selective delivery of H2 S to mitochondria may be therapeutically applicable for employing the cardioprotective utility of H2 S.
Authors: Junhui Sun; Angel M Aponte; Sara Menazza; Marjan Gucek; Charles Steenbergen; Elizabeth Murphy Journal: Cardiovasc Res Date: 2016-02-17 Impact factor: 10.787
Authors: Qutuba G Karwi; Julia Bornbaum; Kerstin Boengler; Roberta Torregrossa; Matthew Whiteman; Mark E Wood; Rainer Schulz; Gary F Baxter Journal: Br J Pharmacol Date: 2017-01-24 Impact factor: 8.739
Authors: John W Elrod; John W Calvert; Joanna Morrison; Jeannette E Doeller; David W Kraus; Ling Tao; Xiangying Jiao; Rosario Scalia; Levente Kiss; Csaba Szabo; Hideo Kimura; Chi-Wing Chow; David J Lefer Journal: Proc Natl Acad Sci U S A Date: 2007-09-18 Impact factor: 11.205
Authors: Carmen Methner; Robert Lukowski; Karina Grube; Florian Loga; Robin A J Smith; Michael P Murphy; Franz Hofmann; Thomas Krieg Journal: Basic Res Cardiol Date: 2013-02-20 Impact factor: 17.165
Authors: Elizabeth Murphy; Hossein Ardehali; Robert S Balaban; Fabio DiLisa; Gerald W Dorn; Richard N Kitsis; Kinya Otsu; Peipei Ping; Rosario Rizzuto; Michael N Sack; Douglas Wallace; Richard J Youle Journal: Circ Res Date: 2016-04-28 Impact factor: 17.367
Authors: Qutuba G Karwi; Julia Bornbaum; Kerstin Boengler; Roberta Torregrossa; Matthew Whiteman; Mark E Wood; Rainer Schulz; Gary F Baxter Journal: Br J Pharmacol Date: 2017-01-24 Impact factor: 8.739
Authors: Claire L Allen; Katarzyna Wolanska; Naseeb K Malhi; Andrew V Benest; Mark E Wood; Winfried Amoaku; Roberta Torregrossa; Matthew Whiteman; David O Bates; Jacqueline L Whatmore Journal: Front Cell Dev Biol Date: 2021-09-07